Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Vertex (VRTX) PT Raised to $200 at Baird; Triple Update and Strong ResultsFebruary 1, 2018 9:09 AM Vertex (VRTX) PT Raised to $203 at CitiFebruary 1, 2018 5:19 AM Vertex (VRTX) PT Raised to $193 at Deutsche BankFebruary 1, 2018 5:14 AM Vertex (VRTX) PT Raised to $200 at BarclaysFebruary 1, 2018 3:48 AM Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic FibrosisFebruary 1, 2018 12:05 AM Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Revenues BeatJanuary 31, 2018 4:17 PM